A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
Phase 1
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: HP568 in combination with palbociclib
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT06757335
A Phase I/II Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Phase 1
Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: HP518 - Dose EscalationDrug: HP518 -Dose Expansion
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT06155084
- Locations
- π¨π³
The Second Hospital Of Anhui Medical University, Hefei, Anhui, China
π¨π³Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
π¨π³Chongqing University Cancer Hospital, Chongqing, Chongqing, China
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 417
- Registration Number
- NCT03851640
- Locations
- π¨π³
Fudan University Shanghai Cancer Center, Shanghai, China
A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch
Phase 1
Completed
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03778047
- Locations
- π¨π³
Medical Ethics Committee of Hunan Cancer Hospital, Changsha, China
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03776968
- Locations
- π¨π³
Shanghai Changhai Hospital Ethics Committee, Shanghai, China
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT03774056
- Locations
- π¨π³
Hinova Pharmaceuticals Inc., Chengdu, Sichuan, China
Β© Copyright 2025. All Rights Reserved by MedPath